Investigational drug · Phase 2
XTMAB-16
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Pulmonary Sarcoidosis.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
4
Any phase or sponsor naming "XTMAB-16"
First trial start
2023
Nov 10, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "XTMAB-16", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pulmonary Sarcoidosis
Largest trials
Live from ClinicalTrials.gov: studies naming "XTMAB-16" as an intervention, largest first.
- An Efficacy Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary ManifestationsPivotal-lookingNot yet recruiting
Xentria, Inc.Industry
NCT07680166 · 182 participants (planned) · Start Oct 30, 2026 · Primary completion Oct 31, 2029
Drug: XTMAB-16; Placebo · For: Pulmonary Sarcoidosis
- Study of Multiple-Ascending-Dose Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary ManifestationsActive, not recruiting
Xentria, Inc.Industry
NCT05890729 · 32 participants (planned) · Start Nov 10, 2023 · Primary completion Nov 30, 2026
Drug: XTMAB-16 or Placebo · For: Pulmonary Sarcoidosis
Sites: Birmingham, Alabama; Denver, Colorado; Jacksonville, Florida · 33 sites in all
Xentria, Inc.Industry
NCT06169397 · 31 participants · Start Mar 1, 2024 · Primary completion Oct 9, 2026
Drug: XTMAB-16 · For: Pulmonary Sarcoidosis
Sites: Denver, Colorado; Chicago, Illinois; Greenville, North Carolina · 11 sites in all
Xentria, Inc.Industry
NCT04971395 · 25 participants · Start Jun 25, 2021 · Primary completion Mar 18, 2022
Drug: Placebo; XTMAB-16 2 mg/kg and 1 more · For: Healthy Participants
Sites: Baltimore, Maryland
Newest research
PubMed records naming it or its code names, newest first.
- Leveraging in vitro and pharmacokinetic models to support bench to bedside investigation of XTMAB-16 as a novel pulmonary sarcoidosis treatment.
Offman E, Singh N, Julian MW, et al. · Front Pharmacol 2023
Also in development for Pulmonary Sarcoidosis
- MK-7240PRA023, TulisokibartPhase 310 trials
Merck & Co. · Ulcerative Colitis, Psoriatic Arthritis, Crohn's Disease
- ATYR1923KRP-R120, EfzofitimodPhase 32 trials
aTyr Pharma, Inc. · Interstitial Lung Disease, Pulmonary Sarcoidosis
- OATD-01Phase 21 trial
Molecure S.A. · Pulmonary Sarcoidosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.